Advancing Cancer Care Through the Power of Learning
eScientiq is a US medical education company focused on advancing the knowledge and clinical expertise of oncologists and hematologists through high-quality learning experiences.
With our dedication to oncology and hematology, we deliver evidence-based educational programs that reflects the latest advancements in diagnosis, treatment, and patient care designed to meet the evolving needs of cancer care professionals.
Majority of our programs are delivered in a virtual format, offering doctors flexible, accessible learning opportunities that integrate seamlessly into their demanding schedules. As an ACCME-accredited provider, we ensure that all our programs meet the highest standards of continuing medical education. From interactive webinars and expert-led case discussions to on-demand modules and CME-certified courses, our content is developed in collaboration with top oncology thought leaders and tailored to reflect the latest advancements in research, treatment, and patient care.
We equip oncologists and haematologists with practical knowledge that can be immediately applied in clinical settings.
Objectives of our work are twofold: to strengthen clinical decision-making and treatment confidence among oncology professionals, and to improve outcomes for the patients they serve.
By closing knowledge gaps and keeping doctors up to date with rapidly evolving standards of care, we enhance the quality, consistency, and personalization of cancer treatment across the USA.
Thank you for your interest in this educational program!
To visit the registration page please confirm that you are a Licensed Healthcare Professional
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Accredited Continuing Medical Education Programs
March - April 2025
Mysterious Myeloma: Emerging Therapies and CAR T-cell Therapy for Treatment of Multiple Myeloma
These insightful and informative webinars on the latest advancements in the treatment of multiple myeloma will bring together leading experts in the field and to start a discussion on cutting-edge therapies, clinical trials, and personalized treatment options for patients with myeloma. The webinars will provide valuable insights into the current landscape of myeloma care and the promising future of treatment options.
.webp)
July - November 2025
MCL unlocked: Mastering Mantle Cell Lymphoma
Delve deeper into the knowledge of MCL and its challenges, educational needs, treatment approaches, obstacles to treatment, and patient management through a series of webinars.
July - November 2025
CLLever: Series of Educational Webinars on Chronic Lymphocytic Leukemia (CLL)
A series of webinars on CLL can play a pivotal role in addressing the current challenges and unmet needs in the treatment and management of this disease. By facilitating education, collaboration, and resource sharing, these webinars can help improve patient outcomes and enhance the overall care landscape for those affected by CLL.
August - December 2025
OASIS: Series of Webinars on Opioid Awareness, Safety, and Intervention Strategies
The OASIS Drug Enforcement Administration (DEA) Pain Management and Substance Use Disorders (SUDs) Education Program is a virtual continuing education (CE) initiative designed to address critical gaps in understanding and managing pain in cancer patients and other chronic pain patients, particularly in the context of opioid use and associated risks. The program will offer a series of webinars focused on equipping healthcare professionals with the skills to balance effective pain management with the need to reduce the risk of opioid misuse and manage SUDs in pain management and oncology care.
2025
HepaCare: Exploring Innovative Solutions and Vital Research in HCC Among Young Researchers
Elevate your knowledge of HCC through a comprehensive series of workshops and lectures designed to deepen clinical and research expertise. This program fosters a mentor-mentee partnership, offering training in cutting-edge research methodologies and collaborative projects. Participants will develop essential research skills under the guidance of leading experts, culminating in a prestigious grand reward for outstanding contributions to HCC advancement.
2025
BrEaST: Rising Star Research Award: Mentor and Mentee Educational Program for HR2+/HER2- mBC
To address the pressing issue of motivating young oncologists and fostering a sustainable medical oncology workforce, a series of lectures and workshops will be organized. These activities will aim to provide support, resources, and inspiration to young oncologists, addressing the challenges they face and offering strategies to combat burnout and promote career satisfaction.
September 2025 - June 2026
NEXT: Navigating Excellence in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive and Negative (HR+/HER2+ and HER2-) Biomarker Treatment
The NEXT program’s educational series on HR+ mBC biomarkers addresses critical challenges and unmet needs in the treatment of mBC. By fostering education, collaboration, and evidence-based resource sharing, this program aims to improve clinical decision-making, personalize patient care, and ultimately enhance outcomes for those affected by this complex disease.
Projects and Publications supported by eScientiq
The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2- mBC (RETRACT) survey
The RETRACT was designed to evaluate real-world practice patterns in the testing and management of this disease by US oncologists. A Steering Committee of clinicians who are experts in the treatment of breast cancer was recruited through recommendations by Professor Hope S. Rugo. The survey questions were answered via an online platform and the data were anonymized before analysis. A total of 150 oncologists practicing at academic and community centers completed the survey. The results showed this sample of oncologists largely followed recommended best practices for testing biomarkers, selecting treatments, and managing adverse events. However, several items did show substantial minorities of oncologists not in alignment with recommendations in areas including the definition and treatment of visceral crisis, ideal treatment for patients with endocrine resistance, the routine use of next-generation sequencing for biomarker testing, and the use of prophylactic measures for treatment-related adverse events.
The RETRACT was designed to evaluate real-world practice patterns in the testing and management of this disease by US oncologists. A Steering Committee of clinicians who are experts in the treatment of breast cancer was recruited through recommendations by Professor Hope S. Rugo. The survey questions were answered via an online platform and the data were anonymized before analysis. A total of 150 oncologists practicing at academic and community centers completed the survey. The results showed this sample of oncologists largely followed recommended best practices for testing biomarkers, selecting treatments, and managing adverse events. However, several items did show substantial minorities of oncologists not in alignment with recommendations in areas including the definition and treatment of visceral crisis, ideal treatment for patients with endocrine resistance, the routine use of next-generation sequencing for biomarker testing, and the use of prophylactic measures for treatment-related adverse events.
San Antonio Breast Cancer Symposium 2024
.png)
Real-World Treatment Challenges in HR+/HER2- mBC: Results from the RETRACT Survey of 150 US Oncologists
Authors: Hope Rugo, Aditya Bardia, William Gradishar, Erika Hamilton, Sara Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara Tolaney
Abstract number – P2-08-03
Real-World Treatment Challenges in HR+/HER2- mBC: Results from the RETRACT Survey of 150 US Oncologists
Authors: Hope Rugo, Aditya Bardia, William Gradishar, Erika Hamilton, Sara Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara Tolaney
Abstract number – P2-08-03
American Society of Clinical Oncology 2025
Opinions of Real-World Clinicians Regarding Visceral Crisis in HR+/HER2-mBC: Results from the RETRACT Survey of US Oncologists
Authors: Hope Rugo, Aditya Bardia, William Gradishar, Erika Hamilton, Sara Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara Tolaney
Abstract number 504196
Opinions of Real-World Clinicians on Endocrine Resistance in HR+/HER2-mBC: Results from the RETRACT Survey of US Oncologists
Authors: Hope Rugo, Aditya Bardia, William Gradishar, Erika Hamilton, Sara Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara Tolaney
Abstract number 495986
The Breast
Authors: Hope Rugo, Aditya Bardia, William Gradishar, Erika Hamilton, Sara Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara Tolaney
Abstract number YBRST_104485
RETRACT Project Sponsors
Our Mission
We are on a mission to improve physicians’ competencies such as medical knowledge in the oncology space by organizing and delivering educational events, expert forums, and networking opportunities by capitalizing on eScientiq, a unique and versatile digital platform.
Our medical education events enable clinicians to access state-of-the-art knowledge and to interact with leading oncology experts with the goal of fostering evidence-based practice with a focus on patient-centered care and interdisciplinary teamwork to improve patient quality of life, functional status, and ultimately prolong their survival.
What we do?
Medical Education
eScientiq offers a versatile platform catering to the needs of medical scientists and healthcare providers by providing them with access to cutting-edge medical advancements, facilitating license renewal, providing pivotal healthcare training, and offering a comprehensive repertoire of educational content
Consensus on treatment practise
eScientiq empowers foremost specialists, HCPs, medical oncologists, pathologists, pharmacists, and other accomplished members of multidisciplinary teams to engage in profound discourse, reach a consensus, and concur on the most effective treatment options for the most intricate oncological cases
Surveys across medical professionals
With eScientiq, the team members possess the capability to commence and execute surveys whilst also allowing for participation in said surveys. Additionally, it allows provisions for publication of survey results in multiple reputable scientific journals
Key focus areas
Our digital platform enables Health Care Professionals to connect, correspond, and engage with global oncology specialists and care givers in key focus areas
Lung Cancer
eScientiq provides medical research materials, updates, and discussions related to lung cancer. Health care professionals specializing in oncology can access this information on the platform to augment their understanding, improve patient care, and engage with global oncology specialists and caregivers in this area.
Rare Cancer
eScientiq offers a unique portal for parsing core medical research materials and content related to rare cancers. Health care professionals can access and utilize this specialized information to enhance their knowledge, treatment strategies, and patient care in the context of rare cancer types.
Breast Cancer
eScientiq's digital platform focuses on breast cancer by providing medical professionals with access to relevant research materials and updates. It facilitates connections and correspondence with global oncology specialists, enabling health care professionals to stay up to date with the latest advancements and consensus on breast cancer treatment practices.
GI
eScientiq serves as a portal for health care professionals to access and parse medical research materials, clinical care integrations, and discussions related to GI cancers. This enables professionals to connect with global oncology specialists and caregivers and stay informed about the latest updates and advancements in the diagnosis and treatment of gastrointestinal cancers.
GU
The eScientiq platform caters to health care professionals specializing in GU cancers by providing research materials, clinical care integrations, and discussions related to this specific cancer type. It facilitates connections, consensus-building, and knowledge exchange among professionals, enhancing their ability to access key updates and advancements in the field of genitourinary cancers.
OncoHematology
eScientiq's platform supports health care professionals in the field of OncoHematology by providing access to research materials, clinical care integrations, and real-time discussions. This allows professionals to stay updated with the latest advancements and treatment practices specific to hematological malignancies, facilitating improved patient care in this specialized area of oncology.
